ArticleGigaScience2026
Integrative single-cell transcriptomics and proteomics reveal an immunometabolic framework for MSC-exosome-mediated remodeling of expanded NK cells.
Article in GigaScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundNatural killer (NK) cells play a central role in anti-tumor immunity and immunosurveillance of senescence, yet their clinical performance is frequently limited by functional exhaustion during ex vivo expansion. Mesenchymal stem cell-derived exosomes (MSC-Exos) are increasingly recognized as immunomodulators, but their broader effects on NK cell fitness and functional states remain incompletely characterized.
resultsHere, we assessed MSC-Exos-mediated regulation of human NK cells using a standardized ex vivo priming platform integrated with single-cell transcriptomics and proteomic profiling. MSC-Exos significantly improved NK cell viability in a dose- and time-dependent manner while preserving a CD56⁺CD3- NK cell-enriched phenotype. MSC-Exos-treated NK cells showed enhanced cytotoxicity against K562 tumor cells and senescent fibroblasts. This phenotype was accompanied by increased expression of the activating receptors NKG2D and CD16, reduced LAG3 expression, and enhanced granzyme B expression and degranulation. Consistent with improved NK cell fitness, MSC-Exos treatment was also associated with upregulated expression of genes involved in NRF2-linked redox programs and improved mitochondrial readouts in NK cells. Single-cell analyses of MSC-Exos-treated NK cells revealed enhanced immune-effector programs and reduced inflammatory stress, while trajectory inference indicated that MSC-Exos may bias the NK cell state distribution toward more cytotoxic effector-like states. Proteomic profiling of MSC-Exos identified enrichment of FcγR-associated signaling components, supporting the hypothesis that exosomal composition may be related to the FcγR/CD16-associated transcriptional and phenotypic features observed in MSC-Exos-treated NK cells.
conclusionsOur data indicate that MSC-Exos improve NK cell viability and functional fitness during ex vivo expansion and bias NK cells toward a more effector-cytotoxic state. Together, these findings provide an immunometabolic framework for MSC-Exos-assisted NK cell manufacturing while underscoring the need for further causal validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.